AI
Tuesday, February 25, 2014 2:19:32 PM
TRXC Chart/DD - New Leg for this stock. Up on Volume grtr than 20MA VOL
TransEnterix (OTCQB:TRXC): $1.56
TransEnterix is a small cap medical device company that is awaiting FDA approval for its surgical robot, The Surgibot, which is based on its unique Spider System technology. The device is expected to be approved in 2014, and offers several advantages to Intuitive Surgical's Da Vinci System. The Surgibot is a minimally invasive surgical platform that utilizes a single incision that is about the size of a dime. The system has a much smaller footprint than the Da Vinci, will be considerably cheaper for hospitals, and allows surgeons to operate by the patient's side. A brief demonstration of the Spider System technology can be viewed here.
The company is led by Todd Pope, former executive of Johnson and Johnson, and plans to present at the Stifel Nicolaus MedTech Madness 2013 event on December 16th. The strong likelihood of the Surgibot gaining FDA approval and the disruptive potential that the device possesses makes shares very attractive at these levels, which haven't been touched since the reverse merger between TransEnterix and Safestitch Medical was closed in September.
TransEnterix (OTCQB:TRXC): $1.56
TransEnterix is a small cap medical device company that is awaiting FDA approval for its surgical robot, The Surgibot, which is based on its unique Spider System technology. The device is expected to be approved in 2014, and offers several advantages to Intuitive Surgical's Da Vinci System. The Surgibot is a minimally invasive surgical platform that utilizes a single incision that is about the size of a dime. The system has a much smaller footprint than the Da Vinci, will be considerably cheaper for hospitals, and allows surgeons to operate by the patient's side. A brief demonstration of the Spider System technology can be viewed here.
The company is led by Todd Pope, former executive of Johnson and Johnson, and plans to present at the Stifel Nicolaus MedTech Madness 2013 event on December 16th. The strong likelihood of the Surgibot gaining FDA approval and the disruptive potential that the device possesses makes shares very attractive at these levels, which haven't been touched since the reverse merger between TransEnterix and Safestitch Medical was closed in September.
Watch your thoughts; they become words.
Watch your words; they become actions.
Watch your actions; they become habits.
Watch your habits; they become character.
Watch your character; it becomes your destiny.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
